Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
brexucabtagene autoleucel Susp (OTHER 358652) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved June 26, 2026 , from http://ppman.hank.ai/transparency/procedure/358652/by-state?code_type=OTHER
“brexucabtagene autoleucel Susp (OTHER 358652) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/358652/by-state?code_type=OTHER. Accessed
June 26, 2026 .
“brexucabtagene autoleucel Susp (OTHER 358652) by State,” HANK Price Transparency ,
accessed June 26, 2026 ,
http://ppman.hank.ai/transparency/procedure/358652/by-state?code_type=OTHER.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
OTHER · across United States
358652 — Brexucabtagene Autoleucel Susp
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$623,700
National median
$489,450 – $888,426
IQR (p25 – p75)
3
hospitals filing
1
states
Walking in without insurance?
Cash / self-pay price
Cash median
$498,960
vs. negotiated
-20.0%
Hospitals reporting
3
Cash / self-pay rates apply when you don't run the bill through insurance.
Many hospitals also offer income-based discounts on top of the published
cash price — always ask about a financial-assistance application
before paying.
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 358652 (OTHER), with interquartile range
State Median p25 p75
NE $623,700 $489,450 $888,426